VFC Update Regarding Limited Nirsevimab (Beyfortus™) Vaccine Supply

Dear VFC Provider,

Due to limited supplies, CDC issued a pause of nirsevimab (Beyfortus™) ordering in US VFC programs. The California VFC Program sent a notification on October 16 to VFC providers alerting that Beyfortus™ is temporarily unavailable for ordering in myVFCvaccines.

Nirsevimab supplies are expected to be limited in both the public and private sector throughout the 2023-2024 RSV season. CDC is allocating small volumes of nirsevimab to state VFC programs every few weeks.

We expect to open up ordering of California’s next limited allocation of nirsevimab by early next week to some VFC providers - Details on ordering will be forthcoming. Orders approved before the
shortage have since been processed and shipped, but may have been reduced because of the shortage.

**NO Vaccine Borrowing**
The California VFC program does not permit borrowing of vaccine between VFC and other inventories. Earlier this fall, CDC had allowed states to consider borrowing, but this flexibility is no longer feasible given the shortage.

VFC Providers are not allowed to use VFC doses in privately insured individuals or vice versa. Private doses administered to VFC eligible children may not be replaced by the VFC Program given limited vaccine supplies.

**Recommended use of scarce nirsevimab supplies**
CDC has issued interim clinical recommendations to protect infants from RSV during the shortage: [Health Alert Network (HAN) - 00499 | Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season](https://www.cdc.gov/mmwr/volumes/71/wr/mm7149d5.htm)

Thank you,